Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant

NCT05027425 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

8

Enrollment

OTHER

Sponsor class

Stopped The study is closing due to low enrollment and feasibility of the study.

Conditions

Hepatocellular Carcinoma
Cirrhosis
Portal Hypertension

Interventions

DRUG: Durvalumab
DRUG: Tremelimumab
PROCEDURE: Liver Transplant

Sponsor

University of Cincinnati